Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.46 |
| ▸ | IL1B | P01584 | 3/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | CFD | P00746 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24067349 | 0.93 | CNR1 (0.43) | CNR1IL1BP2RX7CNR2ALDH1A1 | |
| SCHEMBL22450855 | 0.91 | CNR1 (0.46) | CNR1IL1BP2RX7CNR2AAK1 | |
| SCHEMBL22450721 | 0.88 | CNR1 (0.41) | CNR1IL1BP2RX7CNR2ALDH1A1 | |
| SCHEMBL24067313 | 0.86 | IL1B (0.36) | CNR1IL1BP2RX7AAK1CACNA1B | |
| SCHEMBL22450749 | 0.86 | CNR1 (0.37) | CNR1IL1BP2RX7ALDH1A1F2 | |
| SCHEMBL24067399 | 0.85 | ALDH1A1 (0.36) | CNR1ALDH1A1F2PLATPRSS1 | |
| SCHEMBL24067379 | 0.85 | ALDH1A1 (0.36) | CNR1ALDH1A1F2PLATPRSS1 | |
| SCHEMBL22450712 | 0.85 | CNR1 (0.46) | CNR1CNR2 | |
| SCHEMBL24067411 | 0.85 | CNR1 (0.46) | CNR1CNR2 | |
| SCHEMBL22663740 | 0.85 | CNR1 (0.41) | CNR1IL1BP2RX7CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | CHIA TAI TIANGQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-14 | — | — | US | disclosed |
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20220177453-A1 | CRYSTALLIZATION OF SMAC MIMIC USED AS IAP INHIBITOR AND PREPARATION METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | BIRC5, XIAP, BIRC2 | CNR1 4767/4885IL1B 784/4885P2RX7 3029/4885 |
| US-20210371400-A1 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF | BIRC7, BIRC5, BIRC2 | CNR1 4859/4885IL1B 1650/4885P2RX7 3661/4885 |
| US-20220177453-A1 | CRYSTALLIZATION OF SMAC MIMIC USED AS IAP INHIBITOR AND PREPARATION METHOD THEREOF | BIRC2, BIRC7, BIRC3 | CNR1 4819/4885IL1B 982/4885P2RX7 3698/4885 |
| US-11358950-B2 | SMAC mimetics used as IAP inhibitors and use thereof | BIRC7, BIRC5, BIRC2 | CNR1 4859/4885IL1B 1650/4885P2RX7 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.